Remarkably, despite the risk associated to interfering with a central engine of a “housekeeping” process such as RiBi, an inhibitor of Pol I (CX-5461; Drygin et al., 2011) has recently demonstrated sufficient safety in Phase I clinical trials in patients with lymphoma and leukemia, and is now in a Phase I/II study in solid malignancies (although not confined to Myc-driven cancers only). Here, MYC is linked to leukemia.